Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial

被引：2
|
作者：
Green, Jennifer [1 ,2 ]
机构：
[1] Duke Univ, Dept Med, Duke Clin Res Inst, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Div Endocrinol, Durham, NC USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2023年 / 142卷
关键词：
empagliflozin; heart failure; HFpEF; hyperuricemia; SGLT2;
D O I：
10.1016/j.metabol.2023.155468
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0074
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [21] Efficacy of Empagliflozin in Heart Failure with Preserved Ejection Fraction is related to the presence of echocardiographic features of diastolic dysfunction in the EMPEROR-Preserved trial.
    Coats, Andrew
    Butler, Javed
    Zimmet, Hendrik
    Anker, Stefan
    CIRCULATION, 2024, 150
  • [22] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    Tiago Tribolet de Abreu
    Heart Failure Reviews, 2022, 27 : 2077 - 2082
  • [23] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [24] PUBLIC HEALTH IMPACT AND COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE®) IN THE TREATMENT OF PATIENTS WITH HEART FAILURE (HF) WITH PRESERVED EJECTION FRACTION (HFPEF) IN FRANCE, BASED ON EMPEROR-PRESERVED CLINICAL TRIAL
    Levy, P.
    Lamblin, N.
    Groyer, H.
    Chollet, J.
    Tardu, J.
    Linden, S.
    Fauchier, L.
    VALUE IN HEALTH, 2022, 25 (12) : S83 - S83
  • [25] Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Brueckmann, Martina
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zaremba-Pechmann, Liliana
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan
    JAMA CARDIOLOGY, 2023, 8 (07) : 640 - 649
  • [26] Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
    Butler, J.
    EUROPEAN HEART JOURNAL, 2022, 43 : 982 - 982
  • [27] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2021, 18 (11) : 737 - 737
  • [28] Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
    Filippatos, Gerasimos
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 134 - 135
  • [29] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Karina Huynh
    Nature Reviews Cardiology, 2021, 18 : 737 - 737
  • [30] Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
    Ferreira, Joao Pedro
    Zannad, Faiez
    Packer, Milton
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Vasques-Novoa, Francisco
    Boehm, Michael
    Butler, Javed
    Anker, Stefan
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (04) : 952 - 959
12345